Unmet Need in Essential Thrombocythemia and Polycythemia Vera

被引：3
|
作者：
Kishtagari, Ashwin [1 ]
Gerds, Aaron T. [1 ]
机构：
[1] Cleveland Clin, Leukemia & Myeloid Disorders Program, Taussig Canc Inst, 9500 Euclid Ave,CA60, Cleveland, OH 44120 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2021年 / 35卷 / 02期
关键词：
Myeloproliferative neoplasms; MPN; ET; PV; Bomedemstat; IFN-alpha; Idasanutlin; Givinostat;
D O I：
10.1016/j.hoc.2021.01.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Consensus guidelines have helped to standardize the care of patients with essential thrombocythemia and polycythemia vera, focusing on reducing the risk of thrombosis, mitigating symptoms, and avoiding therapies that may accelerate disease progression. However, many unmet needs still exist ranging from the roll of antiplatelet therapy in ET to medications that reduce disease progression. Retrospective studies suggest an improvement in myelofibrosis-free survival for treatment with interferons; new agents are looking to also enact disease modification. © 2021 Elsevier Inc.
引用
收藏
页码：295 / 303
页数：9
相关论文
共 50 条
  • [1] Essential thrombocythemia and polycythemia vera
    Griesshammer, Martin
    Kvasnicka, Hans M. M.
    Koschmieder, Steffen
    ONKOLOGIE, 2023, 29 (04): : 296 - 304
  • [2] Emerging agents and regimens for polycythemia vera and essential thrombocythemia
    Shallis, Rory M.
    Podoltsev, Nikolai A.
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [3] Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
    Sankar, Kamya
    Stein, Brady L.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (12): : 1539 - 1545
  • [4] Emerging agents and regimens for polycythemia vera and essential thrombocythemia
    Rory M. Shallis
    Nikolai A. Podoltsev
    Biomarker Research, 9
  • [5] Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
    Silver, Richard T.
    Kiladjian, Jean-Jacques
    Hasselbalch, Hans Carl
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (01) : 49 - 58
  • [6] Polycythemia vera and essential thrombocythemia: algorithmic approach
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    Tefferi, Ayalew
    CURRENT OPINION IN HEMATOLOGY, 2018, 25 (02) : 112 - 119
  • [7] Updates in the management of polycythemia vera and essential thrombocythemia
    Bose, Prithvirai
    Verstovsek, Srdan
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
  • [8] Treatment options for essential thrombocythemia and polycythemia vera
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    Pieri, Lisa
    Antonioli, Elisabetta
    Bosi, Alberto
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (01) : 41 - 55
  • [9] Contemporary approach to essential thrombocythemia and polycythemia vera
    Aruch, Daniel
    Mascarenhas, John
    CURRENT OPINION IN HEMATOLOGY, 2016, 23 (02) : 150 - 160
  • [10] How to Treat Essential Thrombocythemia and Polycythemia Vera
    Besses, Carlos
    Alvarez-Larran, Alberto
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 : S114 - S123
12345